Course Information

Release date: January 23, 2026
Expiration date: January 23, 2027
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Merck Sharp & Dohme, LLC.

PROGRAM OVERVIEW

Conventional medicine in inflammatory bowel disease (IBD) followed a one-or-two-treatments-fit-all approach. Treatment selection was simple, but outcomes were often poor, yielding no response or intolerable adverse effects. In 2025, a plethora of available treatments across many drug classes has made treatment selection, especially in the second-line, more complicated based on multiple patient variables. The advent of precision medicine takes advantage of new and emerging knowledge about prognostic and predictive biomarkers to more accurately presage disease severity and treatment response. Harnessing these tools to select and monitor response to existing and emerging treatments will enable gastroenterologists and other clinicians to help more patients with Crohn’s disease and ulcerative colitis to achieve clinical and endoscopic remission, yielding improved outcomes.

Join our expert faculty as they explore the evolving therapeutic landscape of IBD and discuss how precision medicine is reshaping clinical decision-making for better, more individualized care.

Learning Objectives

TARGET AUDIENCE

This educational activity has been designed to meet the needs of gastroenterology physicians, gastroenterology fellows, and others involved in the evaluation and treatment of patients with IBD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Analyze the evolution of IBD management from reactive approaches to proactive precision medicine, incorporating risk stratification, biomarkers, and drug-level monitoring to optimize patient outcomes 
Evaluate evidence-based strategies to select appropriate first- and second-line therapy and manage disease complications

Faculty Information and Disclosures

FACULTY CHAIR

Bruce E. Sands, MD, MS, AGAF
Dr. Burrill B. Crohn Professor of Medicine
Icahn School of Medicine at Mount Sinai
System Chief, Division of Gastroenterology
Mount Sinai Health System
New York, New York

FACULTY

Millie D. Long, MD, MPH
Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Millie D. Long, MD, MPH

Consultant: AbbVie, Bristol Myers Squibb, Celltrion, Genentech, Intercept, Janssen, Lilly, Merck, Pfizer, Prometheus, Roche, Roivant, Sanofi, Spyre, Takeda, Target RWE

Grant/Research Support: Celltrion, Lilly, Pfizer, Takeda

Bruce E. Sands, MD, MS, AGAF

Consultant: AbbVie, Abivax, Agomab Therapeutics, Alimentiv, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Galapagos, Gilead Sciences, J&J Innovative Medicine, Janssen, Merck, Pfizer, Sanofi, Takeda, Teva, Ventyx Biosciences

Editorial Support: AbbVie, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, J&J Innovative Medicine, Janssen, Merck, Pfizer, Takeda, Teva, Ventyx Biosciences

Grant/Research Support: Janssen

Stock Options/Stock-Publicly Held Company: Ventyx Biosciences

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of January 23, 2026 through January 23, 2027, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 40% or better and a completed activity evaluation form. A statement of credit will be issued by our system and immediately available to download following your completion of the posttest and evaluation.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Optimizing IBD Outcomes: From Risk Stratification to Therapeutic Monitoring in the Era of Precision Medicine